Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-040865
Filing Date
2021-10-20
Accepted
2021-10-20 19:05:17
Documents
2
Period of Report
2021-10-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5829
2 EX-24 DOCUMENT attachment1.htm EX-24 4061
  Complete submission text file 0000899243-21-040865.txt   11392
Mailing Address C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK NY 10010
Business Address
Corvese Brian (Reporting) CIK: 0001393207 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40908 | Film No.: 211335247

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Issuer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)